Safety and effectiveness of apixaban compared to warfarin in dialysis patients

Research and Practice in Thrombosis and Haemostasis

Volumn 2, Issue 2, 2018, Pages 291-298

  Reed, Daniel ^a   Palkimas, Surabhi ^a   Hockman, Rebecca ^a   Abraham, Sumner ^b   Le, Tri ^a   Maitland, Hillary ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

anticoagulation; apixaban; dialysis; hemorrhage; venous thromboembolism; warfarin

Indexed keywords

APIXABAN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

EID: 85050072768     PISSN: None     EISSN: 24750379     Source Type: Journal    
DOI: 10.1002/rth2.12083     Document Type: Article

References (35)

1. Ocak G, Vossen CY, Rotmans JI, et al. Venous and arterial thrombosis in dialysis patients. Thromb Haemost. 2011;106:1046–52.
2. Tveit DP, Hypolite IO, Hshieh P, et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis. 2002;39:1011–7.
3. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19:135–40.
4. Friberg L, Benson L, Lip GYH. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the swedish atrial fibrillation cohort study. Eur Heart J. 2015;36:297–306.
5. Mitsuma W, Matsubara T, Hatada K, et al. Clinical characteristics of hemodialysis patients with atrial fibrillation: the RAKUEN (registry of atrial fibrillation in chronic kidney disease under hemodialysis from niigata) study. J Cardiol. 2016;68:148–55.
6. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196–203.
7. Harel Z, Sood MM, Perl J. Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2015;24:183–92.
8. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007;50:433–40.
9. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. 2016;149:951–9.
10. Wang TKM, Sathananthan J, Marshall M, Kerr A, Hood C. Relationships between anticoagulation, risk scores and adverse outcomes in dialysis patients with atrial fibrillation. Heart Lung Circ. 2016;25:243–9.
11. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6:2662–8.
12. Li J, Wang L, Hu J, Xu G. Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis. 2015;25:706–13.
13. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223–33.
14. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77:1098–106.
15. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol. 2008;3:1504–10.
16. Fusaro M, Tripepi G, Noale M, et al. Vertebral Fractures and Vascular Calcifications Study Group. Prevalence of vertebral fractures, vascular calcifications, and mortality in warfarin treated hemodialysis patients. Curr Vasc Pharmacol. 2015;13:248–58.
17. Poterucha TJ, Goldhaber SZ. Warfarin and vascular calcification. Am J Med. 2016;129:635.e1–4.
18. Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res. 2006;118:417–22.
19. Schwartzenberg S, Lev EI, Sagie A, Korzets A, Kornowski R. The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease. Am J Cardiol. 2016;117:477–82.
20. Delate T, Witt DM, Jones JR, Bhardwaja B, Senser M. Falsely elevated international normalized ratio values in patients undergoing anticoagulation therapy: a descriptive evaluation. Chest. 2007;131:816–22.
21. Yang F, Hellyer JA, Than C, et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017;103:818–26.
22. Eliquis. (apixaban) [package insert]. Princeton: Bristol-Myers Squibb Company; 2016.
23. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708.
24. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
25. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
26. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.
27. Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628–36.
28. Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241–8.
29. Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017;37:412–9.
30. Steuber TD, Shiltz DL, Cairns AC, Ding Q, Binger KJ, Courtney JR. A multicenter analysis of factors associated with apixaban-related bleeding in hospitalized patients with end-stage renal disease on hemodialysis. Ann Pharmacother 2017;51:954–60.
31. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.
32. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138:1093–100.
33. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.
34. Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2015;66:677–88.
35. Roberts MZ, Farley TM, Owens RE. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment: an alternative viewpoint. Pharmacotherapy. 2017;37:e107–8.